Neuroprotection Peptides

A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.

A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.

A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.

A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.

A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.

A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging.

A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair.

A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue.

An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models.

A naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway.

An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians.

An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome.

A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization.